Loading stock data…
BioLife Solutions, Inc. (BLFS)
$35.38+0.13 (+0.37%)
Market ClosedLast close Sep 8
BioLife Solutions, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioLife Solutions, Inc. in the Healthcare sector is trading at $35.38 with a market capitalization of $1.3B. Wall Street consensus targets $31.29 (7 analysts), implying a -11.6% move over the next 12 months. The stock is currently near its 52-week high of $38.10, remaining 38.7% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply -11.6% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $28.47M↑ | $27.50M↑ | $18.79M↓ | $28.07M↑ | $23.44M |
| Gross Profit | $18.29M↑ | $17.50M↑ | $11.98M↓ | $17.92M↑ | $15.23M |
| Operating Income | $1.70M↑ | $27,000↓ | $1.35M↑ | -$89,000↑ | -$16.13M |
| Net Income | $45.10M↑ | $1.19M↓ | $11.07M↑ | $621,000↑ | -$15.84M |
Peer Comparison
JNJUNHPFE
Fundamentals
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used i...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.33B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.97
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-0.80%
Volume
Today's trading volume
788,038
Recent News
Diamond Hill Bets on BioLife Solutions’ (BLFS) High Switching Cost
Diamond Hill Capital, a First Eagle Investment Management company, issued its Q2 2026 investor letter for its “Small Cap Strategy”. The letter can be downloaded here. The strategy returned 24.01% in the second quarter, outperforming the Russell 2000 Index’s 21.49% return. Performance was positively affected by stock selection in health care and industrials, while the Fund’s underweight position […]
BioLife Solutions (BLFS) Is Up 7.2% After Swinging From Loss To Q2 Profit - What's Changed
In the past quarter, BioLife Solutions, Inc. reported second‑quarter 2026 sales of US$28.47 million, up from US$23.44 million a year earlier, with net income improving to US$45.10 million from a net loss of US$15.84 million. This shift from loss to earnings, including basic earnings per share from continuing operations moving to US$0.92 from a loss of US$0.32, signals a significant change in the company’s recent operating performance. With this sharp move from loss to profit, we’ll examine...
BioLife Solutions, Inc. (BLFS) Q2 Earnings and Revenues Surpass Estimates
BioLife Solutions (BLFS) delivered earnings and revenue surprises of +500.00% and +1.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Repligen (RGEN) Held An M&A Call With BioLife Solutions.
Repligen (NasdaqGS:RGEN) and BioLife Solutions recently held a merger and acquisition call. The discussion focused on potential combinations or partnerships in bioprocessing and cell and gene therapy tools. The call represents new corporate activity that is separate from routine earnings updates. Repligen enters this M&A discussion with BioLife Solutions while its shares trade at $131.06. The stock is up 9.5% over the past year, although it is down 20.3% year to date and has declined 23.6%...
Repligen Reports Q2 Revenue Growth and Raises Full-Year 2026 Guidance
Repligen Corporation (NASDAQ:RGEN) reported double-digit second-quarter revenue growth and increased its full-year 2026 financial guidance, citing strong order momentum and continued market outperformance while highlighting its pending acquisition of BioLife Solutions. Key Investor TakeawaysRepligen raised its full-year 2026 guidance following stronger first-half performance and continued order momentum.